RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
Buy Rating Affirmed for COMPASS Pathways Amid Progress in Pivotal Trials and Strong Financial Position
CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $48
Buy Rating Affirmed: COMPASS Pathways' Promising Clinical Trials Advance Psychedelic Therapeutics
TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
TD Cowen Remains a Buy on COMPASS Pathways (CMPS)
Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $22
Oppenheimer Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $25
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
A Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $23 to $48
Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
Compass Pathways Price Target Cut to $48.00/Share From $50.00 by Canaccord Genuity
Compass Pathways Analyst Ratings
Buy Rating Affirmed for COMPASS Pathways Amid Positive Clinical Trial Progress and Solid Financial Footing
Compass Pathways Analyst Ratings
Compass Pathways Price Target Announced at $23.00/Share by RBC Capital
RBC Capital Initiates Coverage On Compass Pathways With Outperform Rating, Announces Price Target of $23
RBC Initiates COMPASS Pathways at Outperform, Speculative Risk With $23 Price Target
Compass Pathways Analyst Ratings
Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating